Company intelligence / Profile preview

VASTHERA

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

VasThera is a Korea-based pharmaceutical company developing first-in-class synthetic therapeutics targeting redox and autophagy signaling pathways implicated in chronic inflammatory and vascular diseases. Its lead candidate, VTB‑10 for pulmonary arterial hypertension, is expected to enter Phase 1 trials in 2025. The company leverages its proprietary Redoxizyme™ platform to generate small molecule Prx-mimetics that restore cellular redox balance. Additional pipeline programs target cancer, neurodegeneration, and eye disease at the preclinical stage.[1][2][3]

Therapeutic areas: OphthalmologyOncologyCardiovascularNeurology
Modalities: Small moleculesEnzyme mimetics (nanozymes)Biological products[8]
Industry: Biotech

Drug pipeline

4 assets

VT-A1

Preclinical

3 more assets in the full pipeline.

Partnerships

Currently undergoing due diligence for a partnership/licensing-out agreement with strong prospects by end of year; no specific partners named yet.[3]Private equity owner includes Shinhan Venture Investment.[7]

Beyond the preview

Go deeper on VASTHERA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VASTHERA.